Carle Health continues its effort to provide high-quality breast care by now offering the InveniaTM ABUS 2.0 (Automated Breast Ultrasound System) at the Women’s Diagnostic Center in Pekin. ABUS is approved by the Food and Drug Administration for breast cancer screening as an adjunct to mammography for women with dense breast tissue. The installation of this technology in Pekin comes from a generous donation by the Pekin Foundation.
Dense breast tissue can increase risk of developing breast cancer 4 to 6 times (Boyd et al, New England Journal of Medicine 2007;356:227-36.) It also makes cancer more difficult to detect using mammography, according to multiple studies. The difficulty radiologists experience when reading mammograms is that both dense tissue and cancer appear white on a mammogram. With ABUS, suspicious masses appear black against the white dense tissue.
The Invenia ABUS 2.0 system is designed to enhance the consistency, reproducibility, and sensitivity of breast ultrasound, demonstrating a 35.7 percent improvement in cancer detection (sensitivity) in women with dense breasts without prior breast intervention. (FDA PMA Approval P110006, Sept. 18, 2012.) Unlike 2D or 3D mammography, which uses radiation, ABUS screening uses sound waves to create 3D pictures of the breast tissue. Invenia ABUS 2.0 screening along with a screening mammogram will help provide a more complete evaluation of dense breast tissue.
“This is gold standard technology and an incredible investment into the health of our community,” said Ryan Morris, Regional Medical Imaging Director for Carle Health Greater Peoria. “We thank the Pekin Foundation for funding this project and bringing this advanced technology to the area. When patients look to Pekin for imaging services, they deserve a quick, accurate and efficient experience. This technology allows us to provide them that and presents an important and crucial resource for people in the region.”
For more information, visit Carle Health | Your care starts here.
Dense breast tissue can increase risk of developing breast cancer 4 to 6 times (Boyd et al, New England Journal of Medicine 2007;356:227-36.) It also makes cancer more difficult to detect using mammography, according to multiple studies. The difficulty radiologists experience when reading mammograms is that both dense tissue and cancer appear white on a mammogram. With ABUS, suspicious masses appear black against the white dense tissue.
The Invenia ABUS 2.0 system is designed to enhance the consistency, reproducibility, and sensitivity of breast ultrasound, demonstrating a 35.7 percent improvement in cancer detection (sensitivity) in women with dense breasts without prior breast intervention. (FDA PMA Approval P110006, Sept. 18, 2012.) Unlike 2D or 3D mammography, which uses radiation, ABUS screening uses sound waves to create 3D pictures of the breast tissue. Invenia ABUS 2.0 screening along with a screening mammogram will help provide a more complete evaluation of dense breast tissue.
“This is gold standard technology and an incredible investment into the health of our community,” said Ryan Morris, Regional Medical Imaging Director for Carle Health Greater Peoria. “We thank the Pekin Foundation for funding this project and bringing this advanced technology to the area. When patients look to Pekin for imaging services, they deserve a quick, accurate and efficient experience. This technology allows us to provide them that and presents an important and crucial resource for people in the region.”
For more information, visit Carle Health | Your care starts here.
Categories: Community